Stock AnalizAmneal Pharmaceuticals, Inc. AMRX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Amneal Pharmaceuticals, Inc. (AMRX) is a healthcare company listed in the US with a market value of about $7.4B. In the twelve months to September 30, 2026 it had revenue of $3.2B and net income of $133M, a net margin of 4.2%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 50.9, a price to free cash flow of 84.5, 5-year revenue growth of 9% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 75% below the current price.
Score: 1.6 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.0B | $2.8B | $2.4B | $2.2B | $2.1B | $2.0B | $1.6B | $1.7B | $1.0B | $1.0B |
| Net income | $133M | $72M | -$117M | -$84M | -$271M | $13M | $68M | -$604M | -$20M | $0 | $0 |
| Free cash flow | $88M | $270M | $243M | $302M | $19M | $194M | $323M | -$45M | $167M | $139M | -$8M |
| EPS (diluted) | $0.42 | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-0.16 | — | — |
| Net margin | 4.2% | 2.4% | -4.2% | -3.5% | -12.2% | 0.6% | 3.4% | -37.1% | -1.2% | 0.0% | 0.0% |
| ROIC | — | 14.1% | 8.5% | 6.5% | -2.5% | 3.1% | 2.3% | -6.7% | -0.6% | 16.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $24.29, 14% above the current price; targets range from $20.00 to $28.00; the consensus rating is “Strong buy”; expected EPS is $1.07 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Amneal Pharmaceuticals’s P/E ratio?
About 50.9, based on the last twelve months of diluted earnings per share (forward P/E about 19.1).
Is Amneal Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 75% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Amneal Pharmaceuticals pay a dividend?
Not currently.
Is Amneal Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Amneal Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.